Skip to main content

Advertisement

Table 3 Clinical benefit

From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Docetaxel/Oxaliplatin (n = 44)
  Number of Patients Percent 95 % CI
Clinical benefit response 5 11.4 3.79–24.56
Pain intensity (n = 41)    
 Decreased 4 9.8 2.72–23.13
 Stable 29 70.7 54.46–83.87
 Improved 8 19.5 8.82–34.87
Karnofsky Perfomance Score    
 Decreased 16 36.4 22.41–52.23
 Stable 28 63.6 47.77–77.59
Body weight    
 Decreased 40 90.9 78.33–97.47
 Increased 4 9.1 2.53–21.67
  1. 95 % CI confidence interval